Pancreatic Cancer Research Reveals New Insights on Tumor-Intrinsic Interferon Signaling

Strategic Insights -

Fresh data on pancreatic cancer have shed new light on the mechanisms driving cancer resistance to immunotherapy. A recent study published in Frontiers in Immunology has found that tumor-intrinsic interferon (IFN) signaling may contribute to pancreatic cancer cells' ability to evade treatment. Researchers at the University of North Carolina Charlotte successfully engineered chimeric antigen receptor (CAR) T cells to target a specific protein, MUC1, which is overexpressed in over 80% of human pancreatic ductal adenocarcinoma (PDA) cells.

Key Takeaways:

  • The study demonstrated that CAR T cells can target and kill PDA cells, but the effectiveness of this treatment is often limited by the tumor cells' ability to evade the immune response.
  • Tumor-intrinsic IFN signaling is a key factor in this resistance, as it triggers the upregulation of immune checkpoint molecules, such as PD-L1, and the release of chemokines, such as CXCL10.
  • Blocking IFN signaling using a JAK1/2 inhibitor (Ruxolitinib) significantly reduced the tumor cells' ability to evade the immune response, making them more vulnerable to CAR T cell-mediated cytolysis.
  • The study suggests that targeting tumor-intrinsic IFN signaling may be a potential therapeutic strategy to improve the efficacy of CAR T cell therapy in PDA treatment.

Ru Zhou, the lead researcher on the study, commented on the findings, stating, "Taken together, tumor intrinsic IFN signaling may drive immune evasion in PDA cells against tMUC1-targeted T cell-mediated immunotherapy. This identifies tumor IFN signaling as a potential therapeutic target to improve CAR T cell efficacy in PDA treatment."

Statistics:

  • Over 80% of human PDA cells overexpress and aberrantly glycoslate MUC1.
  • CAR T cells can achieve a 90-100% kill rate against PDA cells in vitro and in vivo.
  • Blocking IFN signaling using Ruxolitinib reduces the tumor cells' ability to evade the immune response by 80%.
  • RNA-seq data indicates higher expression of multiple genes along the IFN signaling pathway associated with poor prognosis in PDA patients.

Sources:

  • Tumor-intrinsic interferon signaling drives pancreatic cancer resistance to tumor mucin1-targeted CAR T cell therapy. Frontiers in Immunology, 2025,16. (Frontiers in Immunology - http://journal.frontiersin.org/journal/immunology).
  • NewsRx. University of North Carolina Charlotte Researchers Reveal New Findings on Pancreatic Cancer (Tumor-intrinsic interferon signaling drives pancreatic cancer resistance to tumor mucin1-targeted CAR T cell therapy). Biotech Week. August 27, 2025; p 341.